GT Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by GT Biopharma, Inc. (GTBP) on May 21, 2025, with a signature date of May 27, 2025. The Company, incorporated in Delaware and listed on The Nasdaq Stock Market, operates as a fully remote entity effective July 1, 2024, with no principal executive office.
Key Financial Metrics and Transaction Details
The filing details a private placement of equity securities rather than standard operating financial metrics. Key transaction figures include:
- Initial Offering (May 12, 2025): Up to 6,056 shares of Series L 10% Convertible Preferred Stock with an aggregate stated value of $6,055,555.56 for a purchase price of $5,450,000.00.
- Amended Offering (May 21, 2025): Increased to 6,612 shares of Preferred Stock with an aggregate stated value of $6,611,111.00 for a purchase price of $5,950,000.00.
- Greenshoe Option: Purchasers may elect to purchase additional Preferred Stock with an aggregate stated value of up to $24,018,349 for a purchase price of $21,616,514.
- Warrants: Includes Common Warrants equal to 100% of shares issuable upon conversion of Preferred Stock and Vesting Warrants related to the Greenshoe Right.
The filing does not provide current revenue, profit, cash flow, or debt levels.
Material Changes
The primary material change is the amendment of the Securities Purchase Agreement to increase the size of the preferred stock offering and the addition of a new purchaser. Additionally, the Company filed a Certificate of Increase with the Delaware Secretary of State on May 22, 2025, raising the authorized shares of Series L 10% Convertible Preferred Stock from 28,056 to 30,630 shares.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond the standard disclosures associated with unregistered securities sales. The transaction was conducted pursuant to Rule 506(b) of Regulation D. The Company has agreed to file a registration statement for the public resale of the underlying common stock within 30 days of the initial closing and within 90 days of filing to become effective.
Investor Verification Checklist
- Verify the final closing amount of the $5,950,000 offering and whether the Greenshoe option was exercised.
- Confirm the terms of the Series L 10% Convertible Preferred Stock, specifically the conversion price and dividend accrual rate.
- Review the full text of the First Amendment to the Securities Purchase Agreement (Exhibit 10.1) for any covenants or restrictions.
- Monitor the filing of the registration statement for the resale of common stock as required by the Registration Rights Agreement.
- Check subsequent filings for updated cash position and liquidity status post-closing.